Estrogens and the lower urinary tract

  title={Estrogens and the lower urinary tract},
  author={Dudley Robinson and Linda D. Cardozo},
  journal={Neurourology and Urodynamics},
The urogenital tract is sensitive to the effect of oestrogen and progesterone throughout adult life. Epidemiological studies have implicated oestrogen deficiency in the aetiology of lower urinary tract symptoms occurring following the menopause. Although to date the role of oestrogen replacement therapy in the management of postmenopausal urinary incontinence remains controversial its use in the management of women complaining of urogenital atrophy is now well established. 
Stress urinary incontinence and endogenous sex steroids in postmenopausal women
This study aimed to elucidate the possible relationship between endogenous circulating estrogens and the onset and development of stress urinary incontinence (SUI).
High luteinizing hormone weakens urinary continence mechanisms in association with prostaglandin E2 elevation in a postmenopausal rat model
To explore the role of luteinizing hormone (LH) in the urinary continence mechanism, urethral function was investigated using a postmenopausal rat model with high serum LH concentrations and a gonadotropin releasing hormone (GnRH) antagonist to lower LH concentrations.
An Investigation of Lower Urinary Tract Symptoms in Women Aged 40 and Over
The objective of this study was to determine lower urinary tract symptoms (LUTS) and associated risk factors in women aged 40 years and over.
Changes of Urinary Tract after Menopause and Effectiveness of Menopausal Hormone Replacement Therapy
The current issues on the relationship among urinary tract and sex hormone and menopause, and the effectiveness of menopausal hormone replacement therapy for the treatment of overactive bladders, stress urinary tract incontinence and recurrent urinary tract infection are reviewed.
New approaches to treat women’s urogenital problems
A clinical expansion protocol of mesenchymal stem cells (MSCs) is developed that shows that MSCs can be injected into the defective sphincter urethrae in order to improve its function by restoring the structure and, eventually, maintaining the continence.
Bladder Dysfunction and Urinary Incontinence After the Menopause: Hormones, Drugs, or Surgery?
It seems that there are no beneficial effects in using estrogens therapy, both local and systemic, on stress urinary incontinence, and lifestyle changes and bladder retraining are recommended as first line therapy for overactive bladder symptoms.
The mysteries of menopause and urogynecologic health: clinical and scientific gaps
This review summarizes the epidemiology of the individual PFDs with particular attention to the understanding of the relationship between each PFD and menopausal estrogen levels, and the gaps in science and clinical care that affect menopausal women.
Low-Dose Intravaginal Estriol and Pelvic Floor Rehabilitation in Post-Menopausal Stress Urinary Incontinence
IE added to PFMT, ES and BF is a safe and efficacious first-line therapy in postmenopausal women with SUI, and symptoms scores and incontinence status were statistically significant better in Group 2 when compared to Group 1.
Urinary incontinence: the role of menopause
Hormone deficiency after menopause is unlikely to play a major role in urinary incontinence, according to univariate analysis, while symptoms and bother of urge incontinent were significantly related toMenopause age, whereas this relationship was not found for stress incentinence.


The Effects of Estrogens and Gestagens on the Urethral Pressure Profile in Urinary Continent and Stress Incontinent Women
  • T. Rud
  • Medicine
    Acta obstetricia et gynecologica Scandinavica
  • 1980
The present investigation was performed to study the urodynamic effects of hormones on the lower urinary tract in women by randomly giving E2 and E3 orally in doses of 4–8 mg per day for 3 weeks.
Oestriol in the treatment of postmenopausal urgency: a multicentre study.
The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence
To determine whether oestrogen replacement will produce an improvement in the quantity, or quality, of pelvic collagen in postmenopausal women, a large number of women will undergo surgery.
Low dose oral estriol treatment in elderly women with urogenital infections.
Endocrine status and markers of collagen synthesis and degradation in serum and urogenital tissue from women with and without stress urinary incontinence
To investigate possible differences in androgen/estrogen status between patients with stress urinary incontinence (SUI) and healthy women's and to study possible associations between circulating
Low Dose Oral Estriol Treatment in Elderly Women with Urogenital Infections
Forty‐one female geriatric in‐patients with recurrent urogenital infections took part in a cross‐over intervention study with oral estriol as an alternative to antibiotics.
Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women.
Oestrogen therapy for urinary incontinence in post-menopausal women.
There was little evidence from the trials on the period after oestrogen treatment had finished and none about long-term effects, but there was some evidence that oestrogens used locally (for example vaginal creams or tablets) may improve incontinence, but systemic hormone replacement therapy, using conjugated equine Oestrogen, may makeincontinence worse.